Diametric Capital’s Cogent Biosciences COGT Stock Holding History

Diametric Capital’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-13,728	Closed	-$121K	–	146
2021 Q1	$121K	Buy	+13,728	New	+$132K	0.09%	137

Other funds holding COGT

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Diametric Capital's COGT Position: Q2 2021 in Review

Diametric Capital sold out of Cogent Biosciences (COGT) in Q2 2021, closing a stake of 13,728 shares — an estimated $121K sold.

Diametric Capital first reported a position in COGT in Q1 2021 and held it in 1 quarter. The position peaked at $121K in Q1 2021. 69 funds tracked by Wall St. Rank hold COGT as of Q2 2021.

Diametric Capital reported no remaining Cogent Biosciences position as of Q2 2021 after selling out during the quarter.
Diametric Capital sold 13,728 Cogent Biosciences shares in Q2 2021, an estimated $121K.
Diametric Capital first reported a position in Cogent Biosciences in Q1 2021 and held it in 1 quarter.
Diametric Capital's Cogent Biosciences position peaked at $121K in Q1 2021.
69 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2021.

Based on Diametric Capital's 13F filing for Q2 2021, filed 16 Aug 2021.